Orsenix Presents Positive Final Phase 1 Study Results for Lead Investigational Drug, ORH-2014, at the 24th Congress of European Hematology Association
ORH-2014 was demonstrated to be bioavailable and well-tolerated in all doses of 5, 10, and 15 mg taken orally once...